A scalable system for production of functional pancreatic progenitors from human embryonic stem cells.
A scalable system for production of functional pancreatic progenitors from human embryonic stem cells.
复制标题
DOI:
10.1371/journal.pone.0037004
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Robins AJ
中科院分区:
文献类型:
--
作者:
Schulz TC;Young HY;Agulnick AD;Babin MJ;Baetge EE;Bang AG;Bhoumik A;Cepa I;Cesario RM;Haakmeester C;Kadoya K;Kelly JR;Kerr J;Martinson LA;McLean AB;Moorman MA;Payne JK;Richardson M;Ross KG;Sherrer ES;Song X;Wilson AZ;Brandon EP;Green CE;Kroon EJ;Kelly OG;D'Amour KA;Robins AJ
Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will require the translation of proof-of-principle concepts into a scalable, controlled, and regulated cell manufacturing process. We have previously demonstrated that hESC can be directed to differentiate into pancreatic progenitors that mature into functional glucose-responsive, insulin-secreting cells in vivo. In this study we describe hESC expansion and banking methods and a suspension-based differentiation system, which together underpin an integrated scalable manufacturing process for producing pancreatic progenitors. This system has been optimized for the CyT49 cell line. Accordingly, qualified large-scale single-cell master and working cGMP cell banks of CyT49 have been generated to provide a virtually unlimited starting resource for manufacturing. Upon thaw from these banks, we expanded CyT49 for two weeks in an adherent culture format that achieves 50–100 fold expansion per week. Undifferentiated CyT49 were then aggregated into clusters in dynamic rotational suspension culture, followed by differentiation en masse for two weeks with a four-stage protocol. Numerous scaled differentiation runs generated reproducible and defined population compositions highly enriched for pancreatic cell lineages, as shown by examining mRNA expression at each stage of differentiation and flow cytometry of the final population. Islet-like tissue containing glucose-responsive, insulin-secreting cells was generated upon implantation into mice. By four- to five-months post-engraftment, mature neo-pancreatic tissue was sufficient to protect against streptozotocin (STZ)-induced hyperglycemia. In summary, we have developed a tractable manufacturing process for the generation of functional pancreatic progenitors from hESC on a scale amenable to clinical entry.
登录
查看更多内容
影响因子:
4
作者:
Brimble, SN;Zeng, XM;Schulz, TC
通讯作者:
Schulz, TC
DOI:
10.1006/bbrc.2001.6145
发表时间:
2001-12-21
影响因子:
3.1
作者:
Hosokawa, M;Dolci, W;Thorens, B
通讯作者:
Thorens, B
影响因子:
46.9
作者:
Kroon, Evert;Martinson, Laura A.;Baetge, Emmanuel E.
通讯作者:
Baetge, Emmanuel E.
影响因子:
4.6
作者:
Nostro, M. Cristina;Sarangi, Farida;Keller, Gordon
通讯作者:
Keller, Gordon
DOI:
10.1016/j.bbrc.2007.03.017
发表时间:
2007-05-11
影响因子:
3.1
作者:
Clark, Gregory O.;Yochem, Robert L.;Shamblott, Michael J.
通讯作者:
Shamblott, Michael J.